ANO1 and hepatocellular carcinoma: The shRNA- or siRNA-mediated inhibition of ANO1 suppressed proliferation and invasiveness of human BCA cells [18], lung cancer cells [15], colorectal cancers [17], prostatic cancers [11, 32], hepatocellular carcinomas [10], and head and neck squamous cell carcinomas [25].